From birth-month signatures to global climate gradients, emerging evidence indicates that seasonal light, temperature, and ...
1don MSN
Rallybio shares successful early-stage results for rare disease drug; new trial set for late 2026
Rallybio Corporation RLYB on Tuesday shared results from its Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) clinical trial of RLYB116 for complement-mediated diseases, with its initial ...
Why these new drug moves matter for China Medical System Holdings China Medical System Holdings (SEHK:867) has been busy on two fronts, pairing with Insilico Medicine on AI-powered drug discovery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results